[2024-08-01 17:18:02,711][datasets][INFO] - PyTorch version 2.3.1 available.
[2024-08-01 17:18:02,713][datasets][INFO] - TensorFlow version 2.8.0 available.
Unfinished experiment_folder: testbergen/tmp_bioasq_pubmed_ragged_bge-base-en
experiment_folder testbergen/bioasq_pubmed_ragged_bge-base-en
run_name: bioasq_pubmed_ragged_bge-base-en
dataset_folder: datasets/
index_folder: indexes/
runs_folder: runs/
generated_query_folder: generated_queries/
experiments_folder: testbergen
retrieve_top_k: 50
rerank_top_k: 50
generation_top_k: 5
pyserini_num_threads: 20
processing_num_proc: 40
retriever:
  init_args:
    _target_: models.retrievers.dense.Dense
    model_name: BAAI/bge-base-en-v1.5
    max_len: 512
    pooler:
      _target_: models.retrievers.dense.ClsPooler
    similarity:
      _target_: models.retrievers.dense.CosineSim
    prompt_q: 'Represent this sentence for searching relevant passages: '
  batch_size: 128
  batch_size_sim: 2048
generator:
  init_args:
    _target_: models.generators.vllm.LLM
    model_name: Upstage/SOLAR-10.7B-Instruct-v1.0
    max_new_tokens: 128
    max_length: 4096
    batch_size: 512
dataset:
  dev:
    doc:
      init_args:
        _target_: modules.dataset_processor.PubMed2023_Ragged
        split: train
    query:
      init_args:
        _target_: modules.dataset_processor.BIOASQ11B_Ragged
        split: train
  test:
    doc: null
    query: null
prompt:
  system: You are a helpful assistant. Your task is to extract relevant information
    from provided documents and to answer to questions as briefly as possible.
  user: f"Background:\n{docs}\n\nQuestion:\ {question}"
  system_without_docs: You are a helpful assistant. Answer the questions as briefly
    as possible.
  user_without_docs: f"Question:\ {question}"

Processing dataset PubMed-2023_Ragged in train split 
Processing dataset BIOASQ11B_Ragged in train split 
INFO 08-01 17:18:25 config.py:472] Using fp8 data type to store kv cache. It reduces the GPU memory footprint and boosts the performance. Meanwhile, it may cause accuracy drop without a proper scaling factor
INFO 08-01 17:18:25 llm_engine.py:176] Initializing an LLM engine (v0.5.3.post1) with config: model='Upstage/SOLAR-10.7B-Instruct-v1.0', speculative_config=None, tokenizer='Upstage/SOLAR-10.7B-Instruct-v1.0', skip_tokenizer_init=False, tokenizer_mode=auto, revision=None, rope_scaling=None, rope_theta=None, tokenizer_revision=None, trust_remote_code=False, dtype=torch.float16, max_seq_len=4096, download_dir=None, load_format=LoadFormat.AUTO, tensor_parallel_size=1, pipeline_parallel_size=1, disable_custom_all_reduce=False, quantization=None, enforce_eager=True, kv_cache_dtype=fp8, quantization_param_path=None, device_config=cuda, decoding_config=DecodingConfig(guided_decoding_backend='outlines'), observability_config=ObservabilityConfig(otlp_traces_endpoint=None), seed=0, served_model_name=Upstage/SOLAR-10.7B-Instruct-v1.0, use_v2_block_manager=False, enable_prefix_caching=False)
INFO 08-01 17:18:26 selector.py:151] Cannot use FlashAttention-2 backend for Volta and Turing GPUs.
INFO 08-01 17:18:26 selector.py:54] Using XFormers backend.
INFO 08-01 17:18:27 model_runner.py:680] Starting to load model Upstage/SOLAR-10.7B-Instruct-v1.0...
INFO 08-01 17:18:28 selector.py:151] Cannot use FlashAttention-2 backend for Volta and Turing GPUs.
INFO 08-01 17:18:28 selector.py:54] Using XFormers backend.
INFO 08-01 17:18:28 weight_utils.py:223] Using model weights format ['*.safetensors']
INFO 08-01 17:18:44 model_runner.py:692] Loading model weights took 19.9900 GB
INFO 08-01 17:18:46 gpu_executor.py:102] # GPU blocks: 5012, # CPU blocks: 2730


::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
RAG Model:
Retriever: BAAI/bge-base-en-v1.5
Generator: Upstage/SOLAR-10.7B-Instruct-v1.0
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::


WARNING 08-01 17:21:08 scheduler.py:1125] Sequence group 718 is preempted by PreemptionMode.RECOMPUTE mode because there is not enough KV cache space. This can affect the end-to-end performance. Increase gpu_memory_utilization or tensor_parallel_size to provide more KV cache memory. total_num_cumulative_preemption=1
__________________________________________________
Query ID: 620157bec9dfcb9c09000025
Query: Is there any role of the 'Greek islands' in olfactory receptor choice?
__________________________________________________
Instruction to Generator:
### System:
You are a helpful assistant. Your task is to extract relevant information from provided documents and to answer to questions as briefly as possible.

### User:
Background:
Document 1: Terrestrial chemical cues help coral reef fish larvae locate settlement habitat surrounding islands.: Understanding the degree of connectivity between coastal and island landscapes and nearby coral reefs is vital to the integrated management of terrestrial and marine environments in the tropics. Coral reef fish are capable of navigating appropriate settlement habitats following their pelagic larval phase, but the mechanisms by which they do this are unclear. The importance of olfactory cues in settlement site selection has been demonstrated, and there is increasing evidence that chemical cues from terrestrial sources may be important for some species. Here, we test the olfactory
Document 2: Identification of a uniquely expanded V1R (ORA) gene family in the Japanese grenadier anchovy (: A number of studies have suggested that olfaction plays an important role in fish migration. Fish use several distinct families of olfactory receptors to detect environmental odorants, including MORs (main olfactory receptors), V1Rs (vomeronasal type-1 receptors), V2Rs (vomeronasal type-2 receptors), TAARs (trace amine-associated receptors), and FPRs (formyl peptide receptors). The V1Rs have been reported to detect pheromones, and a pheromone hypothesis for the spawning migration of anadromous fish has been proposed. Examining whether
Document 3: Early events in olfaction: diversity and spatial patterns of odorant receptors.: In the past few years, a major advance was made in understanding early events in olfaction. In particular, a molecular basis for the sense of smell has emerged. I will focus on the most recent data obtained on an extremely large subfamily of putative odorant receptors. These results may explain how the olfactory system can recognize and distinguish thousands of odoriferous molecules and how the spatial coding of odor molecules could be generated in the olfactory epithelium and subsequently transmitted to the olfactory bulb. The putative odor receptors are
Document 4: Strong links between genomic and anatomical diversity in both mammalian olfactory chemosensory systems.: Mammalian olfaction comprises two chemosensory systems: the odorant-detecting main olfactory system (MOS) and the pheromone-detecting vomeronasal system (VNS). Mammals are diverse in their anatomical and genomic emphases on olfactory chemosensation, including the loss or reduction of these systems in some orders. Despite qualitative evidence linking the genomic evolution of the olfactory systems to specific functions and phenotypes, little work has quantitatively tested whether the genomic aspects of the mammalian olfactory chemosensory systems are correlated to anatomical diversity. We show that the genomic and anatomical variation in these
Document 5: Pleasantness of olfactory and trigeminal stimulants in different Italian regions.: Although individuals categorize odors according to their pleasantness, experience may also influence odor perception-a phenomenon that partially explains why different populations perceive odors differently. Italy, which comprises 20 regions, is characterized by very different cultures. In the present study, we investigated for the first time how Italian regional differences can affect odor perception. 254 healthy volunteers coming from northern, central, southern Italy, and Sicily, one of the two major Italian islands, were recruited in Padua, Rome, Naples, and Syracuse, respectively. Olfactory function was tested with Sniffin' Sticks identification subtest. Subjects


Question: Is there any role of the 'Greek islands' in olfactory receptor choice?

### Assistant:


LLM Answer:
There is no mention or indication of a role for Greek islands in olfactory receptor choice within the provided documents. The closest context is Document 1, where it discusses the importance of olfactory cues for coral reef fish in locating settlement habitat around islands, but it does not specifically mention Greek islands.
Label(s):
['yes']


__________________________________________________
Query ID: 5d38577b7bc3fee31f000017
Query: What is the main difference between nascent and mature chromatin?
__________________________________________________
Instruction to Generator:
### System:
You are a helpful assistant. Your task is to extract relevant information from provided documents and to answer to questions as briefly as possible.

### User:
Background:
Document 1: Maturation of nucleosomal and nonnucleosomal components of nascent chromatin: differential requirements for concurrent protein synthesis.: The DNA of newly replicated chromatin is comprised of two components, distinguishable by their solubility characteristics and requirements for maturation. One of these components possesses core histones, typical nucleosomal structure, a nuclease-resistant core containing 146 base pairs (bp) of new DNA, and all the nucleosomal species found in bulk chromatin (due to bound histone H1 and high mobility group proteins). In addition, this class of nascent chromatin exhibits a shortened repeat length of approximately 165 bp, as opposed to the 288-bp repeat of bulk chromatin.
Document 2: [Nascent chromatin composition revealed].
Document 3: Nascent RNA synthesis in the context of chromatin architecture.: Based on the idea that chromatin domains provide physical barriers for large molecules and multi-enzyme complexes, including the components of the transcription machinery, it has been proposed that transcription should be confined to the surfaces of chromatin domains. As a consequence nascent RNA should accumulate in the interchromatin space, which is thought to provide a special nuclear compartment involved in transcription, as well as in the processing and export of RNA (Cremer et al. 1993, Cremer & Cremer 2001). To further address the relationships between chromatin organization and RNA synthesis, we
Document 4: Nascent chromatin occupancy profiling reveals locus- and factor-specific chromatin maturation dynamics behind the DNA replication fork.: Proper regulation and maintenance of the epigenome is necessary to preserve genome function. However, in every cell division, the epigenetic state is disassembled and then reassembled in the wake of the DNA replication fork. Chromatin restoration on nascent DNA is a complex and regulated process that includes nucleosome assembly and remodeling, deposition of histone variants, and the re-establishment of transcription factor binding. To study the genome-wide dynamics of chromatin restoration behind the DNA replication fork, we developed nascent chromatin occupancy profiles (NCOPs) to comprehensively
Document 5: Dual nature of newly replicated chromatin. Evidence for nucleosomal and non-nucleosomal DNA at the site of native replication forks.: When chromatin is extracted from nuclease-digested nuclei by stepwise salt elution, two different classes of newly replicated chromatin can be distinguished. Nascent DNA eluted from nuclei under conditions of low to moderate ionic strength (0.1-0.3 M NaCl) exhibits nucleosomal periodicity and is found in particles which have the same electrophoretic mobility as bona fide H1- or high mobility group protein-containing mononucleosomes. Thus, factors believed to be involved with both the higher order coiling and transcriptionally active state of chromatin are rapidly


Question: What is the main difference between nascent and mature chromatin?

### Assistant:


LLM Answer:
The main difference between nascent and mature chromatin mainly lies in their formation and composition during and after DNA replication. While mature chromatin is fully assembled and organized, nascent chromatin is newly synthesized DNA that has just been replicated. In nascent chromatin, the chromatin structure is in the process of maturation, involving steps such as nucleosome assembly, histone variant deposition, and re-establishment of transcription factor binding. This maturation process gives nascent chromatin shorter repeat lengths and distinctive differential requirements for concurrent protein synthesis compared to mature bulk chromatin.
Label(s):
['lack of H1']


__________________________________________________
Query ID: 58ce5c7c1f5fb2b734000001
Query: List metalloenzyme inhibitors.
__________________________________________________
Instruction to Generator:
### System:
You are a helpful assistant. Your task is to extract relevant information from provided documents and to answer to questions as briefly as possible.

### User:
Background:
Document 1: Investigating the selectivity of metalloenzyme inhibitors.: The inhibitory activity of a broad group of known metalloenzyme inhibitors against a panel of metalloenzymes was evaluated. Clinically approved inhibitors were selected as well as several other reported metalloprotein inhibitors in order to represent a broad range of metal binding groups (MBGs), including hydroxamic acid, carboxylate, hydroxypyridinonate, thiol, and N-hydroxyurea functional groups. A panel of metalloenzymes, including carbonic anhydrase (hCAII), several matrix metalloproteinases (MMPs), angiotensin converting enzyme (ACE), histone deacetylase (HDAC-2), and tyrosinase (TY), was selected based on their clinical importance for a range of pathologies. In addition, each inhibitor was evaluated for
Document 2: A Bioinorganic Approach to Fragment-Based Drug Discovery Targeting Metalloenzymes.: Metal-dependent enzymes (i.e., metalloenzymes) make up a large fraction of all enzymes and are critically important in a wide range of biological processes, including DNA modification, protein homeostasis, antibiotic resistance, and many others. Consequently, metalloenzymes represent a vast and largely untapped space for drug development. The discovery of effective therapeutics that target metalloenzymes lies squarely at the interface of bioinorganic and medicinal chemistry and requires expertise, methods, and strategies from both fields to mount an effective campaign. In this Account, our research program that brings together the principles and methods of
Document 3: Medicinal chemistry of metal chelating fragments in metalloenzyme active sites: A perspective.: Numerous metal-containing enzymes (metalloenzymes) have been considered as drug targets related to diseases such as cancers, diabetes, anemia, AIDS, malaria, bacterial infection, fibrosis, and neurodegenerative diseases. Inhibitors of the metalloenzymes have been developed independently, most of which are mimics of substrates of the corresponding enzymes. However, little attention has been paid to the interactions between inhibitors and active site metal ions. This review is focused on different metal binding fragments and their chelating properties in the metal-containing active binding pockets of metalloenzymes. We have enumerated over one hundred
Document 4: Perspectives in Medicinal Chemistry: Metalloprotein Inhibitors: What Have We Made and What is the Next Step?
Document 5: Combined mass spectrometry and dynamic chemistry approach to identify metalloenzyme inhibitors.


Question: List metalloenzyme inhibitors.

### Assistant:


LLM Answer:
From the provided documents, some examples of metalloenzyme inhibitors include:

1. Inhibitors with hydroxamic acid, carboxylate, hydroxypyridinonate, thiol, and N-hydroxyurea functional groups (Document 1)
2. Inhibitors targeting carbonic anhydrase (hCAII), matrix metalloproteinases (MMPs), angiotensin converting enzyme (ACE), histone deacetylase (HDAC-2), and tyrosinase (TY) (Document 
Label(s):
['VT-1129 VT-1161 hydroxamate molecules siderophores Foscarnet BB-3497']


__________________________________________________
Query ID: 5880be1dc872c95565000007
Query: Which enzyme is inhibited by niraparib?
__________________________________________________
Instruction to Generator:
### System:
You are a helpful assistant. Your task is to extract relevant information from provided documents and to answer to questions as briefly as possible.

### User:
Background:
Document 1: Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.: Poly(ADP-ribose) polymerases (PARPs) are involved in DNA repair following damage by endogenous or exogenous processes. It has become clear over the past decade that inhibition of PARP in the context of defects in other DNA repair mechanisms provide a tumor specific way to kill cancer cells. We describe the rationale for this approach and the design and discovery of niraparib, a potent PARP-1/2 inhibitor with good cell based activity, selectivity for cancer over normal cells, and oral bioavailability. Niraparib was characterized in a number of
Document 2: The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.: Poly(ADP-ribose) polymerase (PARP) is implicated in DNA repair and transcription regulation. Niraparib (MK4827) is an oral potent, selective PARP-1 and PARP-2 inhibitor that induces synthetic lethality in preclinical tumour models with loss of BRCA and PTEN function. We investigated the safety, tolerability, maximum tolerated dose, pharmacokinetic and pharmacodynamic profiles, and preliminary antitumour activity of niraparib.
Document 3: Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine.: Niraparib (MK-4827) is a novel poly(ADP-Ribose) polymerase (PARP) inhibitor currently investigated in phase III clinical trials to treat cancers. The development of a new drug includes the characterisation of absorption, metabolism and excretion (AME) of the compound. AME studies are a requirement of regulatory agencies and for this purpose bioanalytical assays are essential. This article describes the development and validation of a bioanalytical assay for niraparib and its carboxylic acid metabolite M1 in human plasma and urine using liquid chromatography-tandem mass
Document 4: The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer.: Niraparib is a highly selective inhibitor of PARP-1 and PARP-2 approved in the United States for maintenance treatment of adult patients with recurrent ovarian cancer in complete or partial response to platinum-based chemotherapy. In this open-label crossover study, we evaluated the effects of food on niraparib pharmacokinetics (PK) and safety.
Document 5: Nephrotoxicity Associated With Niraparib.


Question: Which enzyme is inhibited by niraparib?

### Assistant:


LLM Answer:
Niraparib is a inhibitor of poly(ADP-ribose) polymerases (PARPs), specifically targeting PARP-1 and PARP-2. This information can be gathered from documents 1, 2, and 2's mention of niraparib being a PARP inhibitor.
Label(s):
['Poly(ADP-ribose) Polymerase']


__________________________________________________
Query ID: 5aa304f1d6d6b54f79000004
Query: Is the consumption of chocolate associated with an increase in cardiovascular disease?
__________________________________________________
Instruction to Generator:
### System:
You are a helpful assistant. Your task is to extract relevant information from provided documents and to answer to questions as briefly as possible.

### User:
Background:
Document 1: Chocolate consumption and risk of cardiovascular diseases: a meta-analysis of prospective studies.: Studies investigating the impact of chocolate consumption on cardiovascular disease (CVD) have reached inconsistent conclusions. As such, a quantitative assessment of the dose-response association between chocolate consumption and incident CVD has not been reported. We performed a systematic review and meta-analysis of studies assessing the risk of CVD with chocolate consumption.
Document 2: Chocolate and cardiovascular disease: a sweet deal?
Document 3: Chocolate intake and heart disease and stroke in the Women's Health Initiative: a prospective analysis.: Three recent meta-analyses found significant prospective inverse associations between chocolate intake and cardiovascular disease risk. Evidence from these meta-analyses suggests that such inverse associations may only apply to elderly individuals or those with pre-existing major chronic disease.
Document 4: Observational studies find association between chocolate consumption and reduced risk of cardiovascular disease and diabetes.
Document 5: Whether higher chocolate consumption is associated with a reduction in risk of coronary artery disease? We are not sure.


Question: Is the consumption of chocolate associated with an increase in cardiovascular disease?

### Assistant:


LLM Answer:
Answer: Based on the provided documents, chocolate consumption appears to have an inconsistent but generally inverse association with cardiovascular disease risk. Some studies and meta-analyses have found a reduced risk, although this association may only apply to specific populations such as elderly individuals or those with pre-existing chronic diseases. Still, the exact relationship isn't conclusively established (Document 5).
Label(s):
['no']


